questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Antienzymes
Inhibiteurs de la phospholipase A2
Inhibiteurs de la phospholipase A2 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Phospholipases
Tests de laboratoire
Tests de laboratoire
Acides gras
Imagerie médicale
Diagnostic
Symptômes
5
Troubles digestifs
Symptômes
Éruptions cutanées
Inflammation
Prévention
5
Prévention
Alimentation équilibrée
Compléments alimentaires
Anti-inflammatoires
Traitements
5
Médicaments anti-inflammatoires
Inhibiteurs
Corticostéroïdes
Inflammation
Plantes médicinales
Traitements naturels
Complications
5
Maladies chroniques
Inflammation
Suivi médical
Gestion des complications
Facteurs de risque
5
Facteurs de risque
Prédispositions génétiques
Obésité
Facteurs de risque
Stress chronique
Inflammation
Antécédents familiaux
Maladies inflammatoires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phospholipase A2 : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de la phospholipase A2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de la phospholipase A2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-18",
"dateModified": "2025-03-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phospholipase A2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antienzymes",
"url": "https://questionsmedicales.fr/mesh/D004791",
"about": {
"@type": "MedicalCondition",
"name": "Antienzymes",
"code": {
"@type": "MedicalCode",
"code": "D004791",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phospholipase A2",
"alternateName": "Phospholipase A2 Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D064801",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "James A Shayman",
"url": "https://questionsmedicales.fr/author/James%20A%20Shayman",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA. Electronic address: jshayman@umich.edu."
}
},
{
"@type": "Person",
"name": "Kathleen Fernandes Grego",
"url": "https://questionsmedicales.fr/author/Kathleen%20Fernandes%20Grego",
"affiliation": {
"@type": "Organization",
"name": "Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil."
}
},
{
"@type": "Person",
"name": "Akira Abe",
"url": "https://questionsmedicales.fr/author/Akira%20Abe",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Science of Bacteria, Tokyo University of Agriculture, Tokyo, Japan. Electronic address: aabe@umich.edu."
}
},
{
"@type": "Person",
"name": "Shulin Hou",
"url": "https://questionsmedicales.fr/author/Shulin%20Hou",
"affiliation": {
"@type": "Organization",
"name": "Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China."
}
},
{
"@type": "Person",
"name": "Junping Bai",
"url": "https://questionsmedicales.fr/author/Junping%20Bai",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan, Shanxi, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Offensive language detection in low resource languages: A use case of Persian language.",
"datePublished": "2024-06-21",
"url": "https://questionsmedicales.fr/article/38905214",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0304166"
}
},
{
"@type": "ScholarlyArticle",
"name": "Geography and language divergence: The case of Andic languages.",
"datePublished": "2022-05-26",
"url": "https://questionsmedicales.fr/article/35617249",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0265460"
}
},
{
"@type": "ScholarlyArticle",
"name": "An investigation across 45 languages and 12 language families reveals a universal language network.",
"datePublished": "2022-07-18",
"url": "https://questionsmedicales.fr/article/35856094",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41593-022-01114-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Language Environment at Home of Children With (a Suspicion of) a Developmental Language Disorder and Relations With Standardized Language Measures.",
"datePublished": "2023-07-07",
"url": "https://questionsmedicales.fr/article/37418756",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2023_JSLHR-23-00066"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adaptive Language Mapping Paradigms for Presurgical Language Mapping.",
"datePublished": "2022-09-22",
"url": "https://questionsmedicales.fr/article/36137653",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3174/ajnr.A7629"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antienzymes",
"item": "https://questionsmedicales.fr/mesh/D004791"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inhibiteurs de la phospholipase A2",
"item": "https://questionsmedicales.fr/mesh/D064801"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de la phospholipase A2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la phospholipase A2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de la phospholipase A2",
"description": "Comment diagnostiquer une inhibition de la phospholipase A2 ?\nQuels tests sont utilisés pour évaluer l'inhibition ?\nY a-t-il des marqueurs spécifiques pour l'inhibition ?\nL'imagerie est-elle utile dans ce diagnostic ?\nQuels symptômes peuvent indiquer une inhibition ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Language#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de la phospholipase A2",
"description": "Quels sont les symptômes d'une inhibition de la phospholipase A2 ?\nL'inhibition provoque-t-elle des douleurs articulaires ?\nY a-t-il des symptômes digestifs associés ?\nLes symptômes varient-ils selon les individus ?\nPeut-on observer des symptômes cutanés ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Language#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de la phospholipase A2",
"description": "Comment prévenir l'inhibition de la phospholipase A2 ?\nLes exercices physiques aident-ils à prévenir l'inhibition ?\nY a-t-il des habitudes à éviter ?\nLes compléments alimentaires sont-ils utiles ?\nLa gestion du stress peut-elle aider ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Language#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de la phospholipase A2",
"description": "Quels traitements existent pour inhiber la phospholipase A2 ?\nLes corticostéroïdes sont-ils efficaces ?\nY a-t-il des traitements naturels disponibles ?\nComment les inhibiteurs spécifiques sont-ils administrés ?\nLes traitements nécessitent-ils un suivi médical ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Language#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de la phospholipase A2",
"description": "Quelles complications peuvent survenir avec l'inhibition ?\nL'inhibition peut-elle entraîner des maladies chroniques ?\nY a-t-il des risques d'allergies ?\nLes complications sont-elles réversibles ?\nComment gérer les complications liées à l'inhibition ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Language#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de la phospholipase A2",
"description": "Quels sont les facteurs de risque d'inhibition ?\nL'obésité est-elle un facteur de risque ?\nLe stress chronique influence-t-il l'inhibition ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'âge est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Language#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inhibition de la phospholipase A2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests biochimiques mesurant l'activité de la phospholipase A2."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'inhibition ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des dosages d'acides gras peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour l'inhibition ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biomarqueurs comme les cytokines peuvent indiquer une inhibition de l'enzyme."
}
},
{
"@type": "Question",
"name": "L'imagerie est-elle utile dans ce diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est généralement pas utilisée pour diagnostiquer l'inhibition de la phospholipase A2."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une inhibition ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes inflammatoires comme la douleur ou le gonflement peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une inhibition de la phospholipase A2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur, inflammation et troubles métaboliques."
}
},
{
"@type": "Question",
"name": "L'inhibition provoque-t-elle des douleurs articulaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'inhibition peut entraîner des douleurs articulaires dues à l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes digestifs associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles digestifs peuvent survenir, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la sensibilité individuelle."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent apparaître en raison de l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'inhibition de la phospholipase A2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir l'inhibition."
}
},
{
"@type": "Question",
"name": "Les exercices physiques aident-ils à prévenir l'inhibition ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut réduire l'inflammation et améliorer la santé globale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabac et l'alcool peut réduire le risque d'inhibition de l'enzyme."
}
},
{
"@type": "Question",
"name": "Les compléments alimentaires sont-ils utiles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains compléments peuvent avoir des effets anti-inflammatoires, mais prudence."
}
},
{
"@type": "Question",
"name": "La gestion du stress peut-elle aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la gestion du stress peut réduire l'inflammation et améliorer la santé."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour inhiber la phospholipase A2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments anti-inflammatoires et des inhibiteurs spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire l'inflammation liée à l'inhibition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels disponibles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent avoir des effets inhibiteurs, mais peu prouvés."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs spécifiques sont-ils administrés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale ou injectable selon le médicament."
}
},
{
"@type": "Question",
"name": "Les traitements nécessitent-ils un suivi médical ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi est essentiel pour ajuster le traitement et surveiller les effets."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'inhibition ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections ou des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "L'inhibition peut-elle entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inhibition prolongée peut contribuer à des maladies inflammatoires chroniques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'allergies ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques peuvent survenir avec certains inhibiteurs de l'enzyme."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'inhibition ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un ajustement du traitement sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'inhibition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'alimentation, le mode de vie et des prédispositions génétiques."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité peut augmenter le risque d'inhibition de la phospholipase A2."
}
},
{
"@type": "Question",
"name": "Le stress chronique influence-t-il l'inhibition ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut exacerber l'inflammation et l'inhibition."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies inflammatoires peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'inhibition peut augmenter avec l'âge en raison de l'inflammation."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 13/03/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA. Electronic address: jshayman@umich.edu.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Department of Molecular Science of Bacteria, Tokyo University of Agriculture, Tokyo, Japan. Electronic address: aabe@umich.edu.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan, Shanxi, China.
Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan, Shanxi, China.
Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan, Shanxi, China.
Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
3 publications dans cette catégorie
Affiliations :
Department of Physiology, College of Korean Medicine, Kyung Hee University, 26-6 Kyungheedae-ro, Dongdamoon-gu, Seoul 02453, Korea.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Departamento de Química, Universidade Federal de Lavras/UFLA, Campus Universitário, Caixa Postal 3037, 37200-000 Lavras, MG, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Programa de Pós-Graduação Interunidades em Biotecnologia (PPIB-IPT, IBU and USP), Universidade de São Paulo (USP), São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Programa de Pós-Graduação Interunidades em Biotecnologia (PPIB-IPT, IBU and USP), Universidade de São Paulo (USP), São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Programa de Pós-Graduação Interunidades em Biotecnologia (PPIB-IPT, IBU and USP), Universidade de São Paulo (USP), São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Departamento de Bioquímica, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
School of Pharmacy, University of Chinese Academy of Sciences, Beijing, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Publications dans "Inhibiteurs de la phospholipase A2" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA.
Publications dans "Inhibiteurs de la phospholipase A2" :
THIS ARTICLE USES WORDS OR LANGUAGE THAT IS CONSIDERED PROFANE, VULGAR, OR OFFENSIVE BY SOME READERS. Different types of abusive content such as offensive language, hate speech, aggression, etc. have ...
We study the correlation between phylogenetic and geographic distances for the languages of the Andic branch of the East Caucasian (Nakh-Daghestanian) language family. For several alternative phylogen...
To understand the architecture of human language, it is critical to examine diverse languages; however, most cognitive neuroscience research has focused on only a handful of primarily Indo-European la...
This study compares the home language environments of children with (a suspicion of) developmental language disorder (DLD) with that of children with typical development (TD). It does so by adopting n...
Ninety-nine 2- to 4-year-old toddlers participated: 59 with (a suspicion of) DLD and 40 with TD. LENA metrics on adult word count, conversational turn count, and child vocalization count were obtained...
We found lower adult word count, conversational turn count, and child vocalization count in the DLD group, independent of multilingualism but not of parental education. In the DLD group, receptive voc...
Toddlers with (a suspicion of) DLD vocalize less at home than children with TD. They also hear fewer adult words and experience fewer conversational turns. Children with DLD's language outcomes are to...
Functional MR imaging is widely used for preoperative language assessment in candidates for resective neurosurgery. Language mapping paradigms that are adaptive to participant performance have the pot...
Seventy-three patients undergoing fMRI for language lateralization and/or localization completed an adaptive semantic matching paradigm, an adaptive phonological judgment paradigm, and two standard pa...
The adaptive semantic paradigm resulted in the most strongly lateralized activation maps, the greatest extent of frontal and temporal activations, and the greatest proportion of overall satisfactory l...
The adaptive language mapping paradigms investigated have several psychometric advantages compared with currently recommended paradigms. Adoption of these paradigms could increase the likelihood of ob...
Life expectancy has been increasing in recent decades. Therefore, it is important to understand the functional changes during healthy ageing. Most research has mainly focused on one linguistic domain ...
Twenty-three older healthy Hebrew-speaking adults, exhibiting no cognitive decline, were examined on tasks aimed at testing their performance in different language and cognitive domains: lexical retri...
A decline was found in several linguistic domains among the older adults, while in other domains no decline was found. However, no unequivocal decline in linguistic functioning was found due to relati...
Not all linguistic domains are equally vulnerable in ageing, and not all older adults are equally affected. The research has both clinical and theoretical implications....
Recent research suggests that speaking a tone language confers benefits in processing pitch in nonlinguistic contexts such as music. This research largely compares speakers of nontone European languag...
Speech-language pathologists (SLPs) have multiple roles and responsibilities related to language and literacy instruction in schools. The purpose of this exploratory, qualitative study was to analyze ...
Eight school-based SLPs participated in a 1-hr virtual focus group conducted via Zoom recording technology. The researchers used a conventional content analysis approach to analyze the focus group dat...
The researchers developed two themes: (a) SLPs identified repeated exposure to books, peer interaction, and teaching vocabulary with visual supports and props as key elements of language and literacy ...
SLPs identified several instructional practices inclusive pre-K teachers could be taught to use during professional development programs to support the emergent literacy development of children with D...
What language devises, it might divide. By exploring the relations among the core geometries of the physical world, the abstract geometry of Euclid, and language, I give new insight into both the pers...
Consequences of multilingualism vary from offering cognitive benefits to poor educational and cognitive outcomes. One aspect of multilingualism that has not been systematically examined is the typolog...